Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $19.96, but opened at $19.19. Pulse Biosciences shares last traded at $19.19, with a volume of 1,747 shares traded.
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research report on Tuesday, August 6th.
View Our Latest Stock Analysis on PLSE
Pulse Biosciences Price Performance
The company's 50-day moving average is $14.82 and its 200-day moving average is $11.17. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -26.95 and a beta of 1.75.
Hedge Funds Weigh In On Pulse Biosciences
A number of hedge funds have recently made changes to their positions in PLSE. BNP Paribas Financial Markets raised its position in shares of Pulse Biosciences by 63.6% in the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company's stock worth $66,000 after buying an additional 2,952 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences in the 1st quarter worth about $88,000. Quest Partners LLC acquired a new position in shares of Pulse Biosciences in the 2nd quarter valued at about $91,000. Cetera Advisors LLC purchased a new stake in shares of Pulse Biosciences during the 1st quarter worth about $109,000. Finally, PNC Financial Services Group Inc. acquired a new stake in Pulse Biosciences during the 4th quarter worth approximately $242,000. Institutional investors and hedge funds own 76.95% of the company's stock.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
See Also
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
